SecurityOCLS / Oculus Innovative Sciences, Inc. (83558L105)
IndustrySurgical and Medical Instruments and Apparatus
Institutional Owners31
Institutional Shares807,204 - 12.57%
Common Shares Outstanding6,421,239 shares (as of 2018-03-31)
Institutional Value$ 3,139,000 USD
Related OCLSW / Oculus Innovative Sciences, Inc.
SNOA / Sonoma Pharmaceuticals, Inc.

Institutional Stock Ownership and Shareholders()

OCLS / Oculus Innovative Sciences, Inc. Institutional Ownership

Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) has 31 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 807,204 shares. Largest shareholders include Bard Associates Inc, Vanguard Group Inc, Sabby Management, LLC, Renaissance Technologies LLC, JW Asset Management, LLC, Janus Capital Management Llc, BlackRock Inc., BlackRock Institutional Trust Company, N.A., National Asset Management, Inc., and Deutsche Bank Ag\.
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/ocls"><img src="https://images.fintel.io/us-ocls-so.png" alt="OCLS / Oculus Innovative Sciences, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2017-02-10 13F-HR BlackRock Advisors LLC 20,202 0 -100.00 5 0 -100.00
2017-02-10 13F-HR BlackRock Fund Advisors 1,009 1,549 53.52 4 8 100.00
2018-05-14 13F-HR BARD ASSOCIATES INC 334,199 327,949 -1.87 1,835 1,207 -34.22
2018-04-10 13F-HR Gradient Investments LLC 285 1
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 3,853 3,853 0.00 21 15 -28.57
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 7 7 0.00 0 0
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 1,014 1,014 0.00 6 4 -33.33
2018-05-14 13F-HR Renaissance Technologies LLC 58,602 58,915 0.53 319 217 -31.97
2018-05-11 13F-HR CITIGROUP INC 34 34 0.00 0 0
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 540 540 0.00 3 2 -33.33
2017-01-13 13F-HR MetLife Securities, Inc 88 88 0.00 0 0
2018-05-14 13F-HR RAYMOND JAMES & ASSOCIATES 0 11,041 0 41
2018-05-15 13F-HR Blackhawk Capital Partners Llc. 485 485 0.00 3 2 -33.33
2018-05-11 13F-HR JW Asset Management, LLC 40,951 40,951 0.00 223 151 -32.29
2018-05-09 13F-HR BlackRock Inc. 28,739 28,907 0.58 157 106 -32.48
2017-05-16 13F-HR JANUS CAPITAL MANAGEMENT LLC 26,873 37,926 41.13 135 272 101.48
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 25,523 0 -100.00 111 0 -100.00
2018-05-15 13F-HR National Asset Management, Inc. 14,802 22,420 51.47 81 83 2.47
2018-05-14 13F-HR MORGAN STANLEY 3,316 3,316 0.00 18 12 -33.33
2018-05-11 13F-HR SEI INVESTMENTS CO 4 4 0.00 0 0
2018-04-10 13F-HR Hartford Financial Management Inc. 500 500 0.00 2 1 -50.00
2018-05-09 13F-HR OPTIMUM INVESTMENT ADVISORS 12 0
2018-05-15 13F-HR DEUTSCHE BANK AG\ 25,141 20,293 -19.28 137 74 -45.99
2018-05-15 13F-HR UBS Group AG 4,444 4,603 3.58 24 17 -29.17
2018-05-15 13F-HR VANGUARD GROUP INC 86,197 101,347 17.58 473 373 -21.14
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 13,177 13,177 0.00 72 48 -33.33
2018-04-24 13F-HR McAdam, LLC 71 0
2018-05-14 13F-HR Premia Global Advisors, Llc 10,000 36
2018-05-15 13F-HR PANAGORA ASSET MANAGEMENT INC 11,919 44
2018-05-15 13F-HR/A Sabby Management, LLC 69,200 255
2018-05-11 13F-HR NORTHERN OAK WEALTH MANAGEMENT INC 117 117 0.00 1 0 -100.00
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 25,523 129
2018-05-04 13F-HR WADE G W & INC 11,000 11,158 1.44 60 41 -31.67

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 83558L105